R. G. Esin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
R. G. Esin has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Oleg Radievich Esin
Kazan Federal University
20 shared publications - Elena A. Gorobets
Kazan Federal University
14 shared publications - I. Kh. Khayrullin
American Canadian School of Medicine
7 shared publications - A. F. Fatykhova
Kazan (Volga Region) Federal University
5 shared publications - Alexandra I. Mashtakova
Kazan Federal University
5 shared publications - D. E. Erkinova
Kazan (Volga Region) Federal University
4 shared publications
Latest Publications
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Cerebral amyloid angiopathy
Cerebral amyloid angiopathy (CAA) is characterized by beta-amyloid deposition within cerebral blood vessels and constitutes an age-related vascular pathology associated with intracerebral hemorrhages and cognitive impairment. CAA is a major contributor to a subtype of stroke with high mortality, morbidity, and recurrence rates. The sporadic, familial, and iatrogenic variants of CAA have distinct epidemiological profiles. Inflammatory mechanisms exacerbate amyloid-induced vascular injury and may cause a distinct subtype of CAA-related inflammation. In 2022, an international collaborative study updated and validated the Boston Diagnostic Criteria (Version 2.0) for CAA across the full spectrum of clinical manifestations. Cognitive impairment in CAA generally manifests in three types: gradual functional decline, stepwise functional decline, and rapidly progressive cognitive deterioration associated with inflammation. CAA is strongly associated with Alzheimer’s disease (AD). While both conditions involve amyloid-β (Aβ) accumulation, their anatomical distributions differ. In AD, Aβ deposits mostly in the frontal and parietal association cortices. CAA is observed in approximately 90% of AD cases, and the coexistence of AD and CAA correlates with more severe disease progression.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Cerebral amyloid angiopathy
Cerebral amyloid angiopathy (CAA) is characterized by beta-amyloid deposition within cerebral blood vessels and constitutes an age-related vascular pathology associated with intracerebral hemorrhages and cognitive impairment. CAA is a major contributor to a subtype of stroke with high mortality, morbidity, and recurrence rates. The sporadic, familial, and iatrogenic variants of CAA have distinct epidemiological profiles. Inflammatory mechanisms exacerbate amyloid-induced vascular injury and may cause a distinct subtype of CAA-related inflammation. In 2022, an international collaborative study updated and validated the Boston Diagnostic Criteria (Version 2.0) for CAA across the full spectrum of clinical manifestations. Cognitive impairment in CAA generally manifests in three types: gradual functional decline, stepwise functional decline, and rapidly progressive cognitive deterioration associated with inflammation. CAA is strongly associated with Alzheimer’s disease (AD). While both conditions involve amyloid-β (Aβ) accumulation, their anatomical distributions differ. In AD, Aβ deposits mostly in the frontal and parietal association cortices. CAA is observed in approximately 90% of AD cases, and the coexistence of AD and CAA correlates with more severe disease progression.
- Open Access
- 14 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 109-114
Restless legs syndrome: Pathogenesis, diagnosis, treatment
Restless Legs syndrome (RLS) occurs in about 3% of adults worldwide. RLS is still poorly diagnosed including due to the lack of screening tools based on verbal descriptors. A literature review was conducted using the eLibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases, based on the keywords “restless legs syndrome”, “pathogenesis”, “diagnosis”, and “reatment”. The search covered a 25-year period. The gathered information was analyzed, systematized, and presented in the following sections: iron deficiency and RLS, genetic predisposition to RLS, the dopaminergic system and RLS, other risk factors and associated conditions, the clinical presentation of RLS, diagnostic criteria for RLS, and RLS treatment. RLS is commonly associated with iron deficiency. There is evidence of a genetic predisposition to RLS. Dopaminergic pathology in RLS is confirmed by the effectiveness of dopaminergic treatment, however, it can cause the phenomenon of augmentation – iatrogenic deterioration, which is characterized by an earlier onset of symptoms in the afternoon than before treatment, the spread of symptoms to the upper extremities and a decrease in the latency period before symptoms appear during periods of rest. Pharmacotherapy (high evidence strength) includes: gabapentin, gabapentin enacarbil, pregabalin, intravenous iron carboxymaltose. Conditionally recommended: intravenous low-molecular-weight iron dextran, ferumoxytol, iron sulfate, dipyridamole, delayed-release oxycodone or other opioids, peroneal nerve stimulation. Drugs that should not be prescribed as standard treatment: levodopa, pramipexole, transdermal rotigotine, ropinirole (can be used to treat RLS in patients who attach more importance to reducing RLS with short-term use and less importance to side effects with prolonged use (especially augmentation)).
- 14 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 109-114
Open AccessRestless legs syndrome: Pathogenesis, diagnosis, treatment
Restless Legs syndrome (RLS) occurs in about 3% of adults worldwide. RLS is still poorly diagnosed including due to the lack of screening tools based on verbal descriptors. A literature review was conducted using the eLibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases, based on the keywords “restless legs syndrome”, “pathogenesis”, “diagnosis”, and “reatment”. The search covered a 25-year period. The gathered information was analyzed, systematized, and presented in the following sections: iron deficiency and RLS, genetic predisposition to RLS, the dopaminergic system and RLS, other risk factors and associated conditions, the clinical presentation of RLS, diagnostic criteria for RLS, and RLS treatment. RLS is commonly associated with iron deficiency. There is evidence of a genetic predisposition to RLS. Dopaminergic pathology in RLS is confirmed by the effectiveness of dopaminergic treatment, however, it can cause the phenomenon of augmentation – iatrogenic deterioration, which is characterized by an earlier onset of symptoms in the afternoon than before treatment, the spread of symptoms to the upper extremities and a decrease in the latency period before symptoms appear during periods of rest. Pharmacotherapy (high evidence strength) includes: gabapentin, gabapentin enacarbil, pregabalin, intravenous iron carboxymaltose. Conditionally recommended: intravenous low-molecular-weight iron dextran, ferumoxytol, iron sulfate, dipyridamole, delayed-release oxycodone or other opioids, peroneal nerve stimulation. Drugs that should not be prescribed as standard treatment: levodopa, pramipexole, transdermal rotigotine, ropinirole (can be used to treat RLS in patients who attach more importance to reducing RLS with short-term use and less importance to side effects with prolonged use (especially augmentation)).
- 14 May 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 35-40
Vestibular cortex and vestibular agnosia
This review analyzes recent literature on the structure of the vestibular cortex. Researchers have identified at least ten brain regions that respond to vestibular stimulation. The vestibular regions identified by caloric, galvanic, and auditory vestibular stimulation are mainly located deep in the lateral sulcus and in the perisylvian cortex around the sylvian fissure. They are also found in the primary somatosensory, posterior parietal, frontal, extrastriate cortex, the cingulate gyrus, and the hippocampus. Together, these regions form the vestibular cortex, a broad network of multisensory regions. Vestibular agnosia as a clinical phenomenon was described in 2021. It is characterized by a decrease or lack of perception of one’s own movements after vestibular stimulation, but normal vestibular reflexes are intact. Possible mechanisms for the development of vestibular agnosia are discussed.
- 14 May 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 35-40
Vestibular cortex and vestibular agnosia
This review analyzes recent literature on the structure of the vestibular cortex. Researchers have identified at least ten brain regions that respond to vestibular stimulation. The vestibular regions identified by caloric, galvanic, and auditory vestibular stimulation are mainly located deep in the lateral sulcus and in the perisylvian cortex around the sylvian fissure. They are also found in the primary somatosensory, posterior parietal, frontal, extrastriate cortex, the cingulate gyrus, and the hippocampus. Together, these regions form the vestibular cortex, a broad network of multisensory regions. Vestibular agnosia as a clinical phenomenon was described in 2021. It is characterized by a decrease or lack of perception of one’s own movements after vestibular stimulation, but normal vestibular reflexes are intact. Possible mechanisms for the development of vestibular agnosia are discussed.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 58-67
Headache in cerebrovascular diseases
Headache is a common symptom of cerebrovascular diseases. This paper presents a literature review with a search depth of 20 years on the clinical features of headache as a criterion for diagnosing or raising clinical suspicion of acute or chronic cerebrovascular disease. The authors studied the most common diseases in clinical practice, focusing on headache causes in the «Headache attributed to cranial or cervical vascular disorder» section of the International Classification of Headache Disorders (3rd edition, 2018). Headaches of various origins are considered: associated with ischemic stroke, thrombosis of the main artery, cerebellar stroke, subarachnoid hemorrhage, arteritis; arising from a transient ischemic attack, with an unruptured arterial aneurysm of the brain, with dissection of the cervical-cephalic arteries, with thrombosis of the veins and sinuses of the brain, with reversible cerebral vasoconstriction syndrome; caused by non-traumatic intracerebral hemorrhage, as well as genetic vasculopathy. The features of the headache assessment in patients with cognitive impairment are addressed.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 58-67
Headache in cerebrovascular diseases
Headache is a common symptom of cerebrovascular diseases. This paper presents a literature review with a search depth of 20 years on the clinical features of headache as a criterion for diagnosing or raising clinical suspicion of acute or chronic cerebrovascular disease. The authors studied the most common diseases in clinical practice, focusing on headache causes in the «Headache attributed to cranial or cervical vascular disorder» section of the International Classification of Headache Disorders (3rd edition, 2018). Headaches of various origins are considered: associated with ischemic stroke, thrombosis of the main artery, cerebellar stroke, subarachnoid hemorrhage, arteritis; arising from a transient ischemic attack, with an unruptured arterial aneurysm of the brain, with dissection of the cervical-cephalic arteries, with thrombosis of the veins and sinuses of the brain, with reversible cerebral vasoconstriction syndrome; caused by non-traumatic intracerebral hemorrhage, as well as genetic vasculopathy. The features of the headache assessment in patients with cognitive impairment are addressed.
- 9 February 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (1) , 77-81
Central sensitization in patients with cerebral small vessel disease
Objective. To evaluate the clinical manifestations of central sensitization in patients with cerebral small vessel disease (CSVD) (with Fazekas II—III white matter hyperintensity). Material and methods. The study included four groups (two test groups and two comparison groups). The test group 1 (TG-Rus) included 50 Russian-speaking patients with a history of CSVD of more than 3 years and a tension and/or cervicogenic headache. The test group 2 (TG-Tat) included 50 Tatar-speaking patients with a history of CSVD of more than 3 years and a tension and/or cervicogenic headache. The comparison groups (CG-Rus and CG-Tat) included 50 Russian-speaking and Tatar-speaking patients with tension and/or cervicogenic headache without CSVD. To assess the central sensitization, the Russian-language and Tatar-language versions of the Central Sensitization Inventory were used. Results. There were statistically significant differences between the test and comparison groups. Significant differences were found in subclinical central sensitization between the TG-Rus and CG-Rus groups (p=0.002), TG-Tat and CG-Tat groups (p=0.001), pronounced differences between the TG-Rus and CG-Rus groups (p=0.03), TG-Tat and CG-Tat groups (p=0.046), and critical differences between TG-Tat and CG-Tat groups (p=0.046). Conclusion. When providing medical care to patients with CSVD, it is necessary to consider the possible comorbidity of pain syndromes and central sensitization, which can burden the clinical presentation and require a special therapeutic strategy.
- 9 February 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (1) , 77-81
Central sensitization in patients with cerebral small vessel disease
Objective. To evaluate the clinical manifestations of central sensitization in patients with cerebral small vessel disease (CSVD) (with Fazekas II—III white matter hyperintensity). Material and methods. The study included four groups (two test groups and two comparison groups). The test group 1 (TG-Rus) included 50 Russian-speaking patients with a history of CSVD of more than 3 years and a tension and/or cervicogenic headache. The test group 2 (TG-Tat) included 50 Tatar-speaking patients with a history of CSVD of more than 3 years and a tension and/or cervicogenic headache. The comparison groups (CG-Rus and CG-Tat) included 50 Russian-speaking and Tatar-speaking patients with tension and/or cervicogenic headache without CSVD. To assess the central sensitization, the Russian-language and Tatar-language versions of the Central Sensitization Inventory were used. Results. There were statistically significant differences between the test and comparison groups. Significant differences were found in subclinical central sensitization between the TG-Rus and CG-Rus groups (p=0.002), TG-Tat and CG-Tat groups (p=0.001), pronounced differences between the TG-Rus and CG-Rus groups (p=0.03), TG-Tat and CG-Tat groups (p=0.046), and critical differences between TG-Tat and CG-Tat groups (p=0.046). Conclusion. When providing medical care to patients with CSVD, it is necessary to consider the possible comorbidity of pain syndromes and central sensitization, which can burden the clinical presentation and require a special therapeutic strategy.
- Open Access
- 11 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 89-94
Anxiety disorders in young adult: Experience of treatment with maritupirdine
Introduction . Anxiety disorders are among the most common mental disorders in the world, having a significant impact on psychological health and social functioning, including adolescents and young adults. These disorders usually manifest themselves at the age of 10–24 years and lead to serious health problems. Aim. To study the clinical features of anxiety disorders within generalized anxiety disorder (GAD), identify the leading manifestations and additional pantomimic, gestural and behavioral marker symptoms, and evaluate the effectiveness of the anxiolytic maritupirdine (Aviandr®) for the treatment of these conditions. Materials and methods. 142 patients with diagnosed clinical-psychopathological and experimental-psychological methods of GAD were examined. Criteria for inclusion in the study: age 18–24 years, patient’s compliance with the criteria of GAD according to DSM-5. Exclusion criteria: the presence of a clinically relevant somatic or neurological disease, pregnancy or pregnancy planning (in women), taking psychotropic drugs during the month preceding inclusion in the study. The Mini-SMILE test, the Spielberger–Khanin test, and the Beck test were used. Patients were prescribed the anxiolytic Aviandr® 20 mg twice daily for 6 weeks. Results. Among the examined young patients with GAD, 6 groups of GAD manifestations and a number of behavioral markers were identified. A statistically significant decrease in scores was noted in the domain of emotional manifestations, on the scales of mental manifestations and symptoms of stress, in the behavioral domain, in somatic manifestations. The largest relative decrease was found on the Beck scale, with situational anxiety in second place in sensitivity to Aviandr®, personal anxiety, and Mini-MIL scores decreased by more than a third. Conclusion. Aviandr® had a positive effect in reducing the severity of GAD.
- 11 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 89-94
Open AccessAnxiety disorders in young adult: Experience of treatment with maritupirdine
Introduction . Anxiety disorders are among the most common mental disorders in the world, having a significant impact on psychological health and social functioning, including adolescents and young adults. These disorders usually manifest themselves at the age of 10–24 years and lead to serious health problems. Aim. To study the clinical features of anxiety disorders within generalized anxiety disorder (GAD), identify the leading manifestations and additional pantomimic, gestural and behavioral marker symptoms, and evaluate the effectiveness of the anxiolytic maritupirdine (Aviandr®) for the treatment of these conditions. Materials and methods. 142 patients with diagnosed clinical-psychopathological and experimental-psychological methods of GAD were examined. Criteria for inclusion in the study: age 18–24 years, patient’s compliance with the criteria of GAD according to DSM-5. Exclusion criteria: the presence of a clinically relevant somatic or neurological disease, pregnancy or pregnancy planning (in women), taking psychotropic drugs during the month preceding inclusion in the study. The Mini-SMILE test, the Spielberger–Khanin test, and the Beck test were used. Patients were prescribed the anxiolytic Aviandr® 20 mg twice daily for 6 weeks. Results. Among the examined young patients with GAD, 6 groups of GAD manifestations and a number of behavioral markers were identified. A statistically significant decrease in scores was noted in the domain of emotional manifestations, on the scales of mental manifestations and symptoms of stress, in the behavioral domain, in somatic manifestations. The largest relative decrease was found on the Beck scale, with situational anxiety in second place in sensitivity to Aviandr®, personal anxiety, and Mini-MIL scores decreased by more than a third. Conclusion. Aviandr® had a positive effect in reducing the severity of GAD.
- Open Access
- 4 December 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 20-27
Levels of central sensitization, anxiety, and depression in patients after ischemic stroke in the early recovery period
Introduction. Post-stroke anxiety, depression, and pain are relevant to medical practice, since they represent a significant obstacle to the effective rehabilitation of patients. Information related to post-stroke anxiety and depression is analyzed in the literature, data on the level of central sensitization (CS) which also indicates the presence of comorbid disorders are insufficient. Furthermore, such studies have not been conducted in samples of native speakers of various languages of the Russian Federation until recently due to the lack of diagnostic tools in these languages. Aim. To compare the levels of СS, anxiety, and depression in patients after ischemic stroke in the early recovery period, using the same instrument in different languages in comparable samples. Materials and methods. The authors analyzed the level of CS, anxiety, and depression in 4 groups. Study groups: 1) Russian-speaking patients who had suffered ischemic stroke (30 people, early recovery period); 2) Tatar-speaking patients who had suffered ischemic stroke (30 people, early recovery period). Comparison groups: 1) Russian-speaking informants without neurological deficit (30 people); 2) Tatar-speaking informants without neurological deficit (30 people). The Central Sensitization Inventory (CSI, Russian and Tatar versions) and the Hospital Anxiety and Depression Scale (HADS, Russian and Tatar versions) were used to assess the level of CSI, depression, and anxiety. Results. Analysis of CSI data revealed statistically significant differences between the study and comparison groups in the subclinical CS parameter. Among stroke patients, the subclinical variant of CS is less common than in healthy controls; clinically significant variants predominate. Statistically significant differences were found in HADS anxiety subscale and HADS depression subscale for both the Russian-speaking and Tatar-speaking study and comparison groups. Conclusion. The data were obtained in samples of native speakers of different languages; the results are comparable, which confirms the universality of the diagnostic scales CSI and HADS for use in the diagnosis of anxiety, depression and CS in post-stroke patients.
- 4 December 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 20-27
Open AccessLevels of central sensitization, anxiety, and depression in patients after ischemic stroke in the early recovery period
Introduction. Post-stroke anxiety, depression, and pain are relevant to medical practice, since they represent a significant obstacle to the effective rehabilitation of patients. Information related to post-stroke anxiety and depression is analyzed in the literature, data on the level of central sensitization (CS) which also indicates the presence of comorbid disorders are insufficient. Furthermore, such studies have not been conducted in samples of native speakers of various languages of the Russian Federation until recently due to the lack of diagnostic tools in these languages. Aim. To compare the levels of СS, anxiety, and depression in patients after ischemic stroke in the early recovery period, using the same instrument in different languages in comparable samples. Materials and methods. The authors analyzed the level of CS, anxiety, and depression in 4 groups. Study groups: 1) Russian-speaking patients who had suffered ischemic stroke (30 people, early recovery period); 2) Tatar-speaking patients who had suffered ischemic stroke (30 people, early recovery period). Comparison groups: 1) Russian-speaking informants without neurological deficit (30 people); 2) Tatar-speaking informants without neurological deficit (30 people). The Central Sensitization Inventory (CSI, Russian and Tatar versions) and the Hospital Anxiety and Depression Scale (HADS, Russian and Tatar versions) were used to assess the level of CSI, depression, and anxiety. Results. Analysis of CSI data revealed statistically significant differences between the study and comparison groups in the subclinical CS parameter. Among stroke patients, the subclinical variant of CS is less common than in healthy controls; clinically significant variants predominate. Statistically significant differences were found in HADS anxiety subscale and HADS depression subscale for both the Russian-speaking and Tatar-speaking study and comparison groups. Conclusion. The data were obtained in samples of native speakers of different languages; the results are comparable, which confirms the universality of the diagnostic scales CSI and HADS for use in the diagnosis of anxiety, depression and CS in post-stroke patients.
- 19 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 36-41
Alexithymia — traditional and advanced studies
The close association of alexithymia with various somatic diseases has been studied for more than fifty years by different medical and related researchers. In the past decade, research on the connection between alexithymia and autoimmune diseases, as well as neurological and mental disorders, has gained significant interest. A literature review with a search depth of 10 years is presented. A literature search was conducted in the elibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases using the key term «alexithymia.» Current evidence suggests a much more heterogeneous understanding of alexithymia in clinical practice during this period: a significant shift has been observed from interpreting alexithymia as a normal variation to considering it a neuropsychiatric syndrome. The paper discusses a new tool for assessing alexithymia, the relationship of alexithymia with post-stroke complications, multiple sclerosis, Parkinson’s disease, epilepsy, tendency to self-harm, and addictive behavior, autism spectrum disorders, post-traumatic stress; analyzes promising areas for further study of alexithymia, aimed at increasing the objectification of its level detection (neuroimaging, search for neurobiological specific features, registration of bioelectrical activity of the brain, and computer diagnostic methods), as well as the development of therapeutic strategies.
- 19 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 36-41
Alexithymia — traditional and advanced studies
The close association of alexithymia with various somatic diseases has been studied for more than fifty years by different medical and related researchers. In the past decade, research on the connection between alexithymia and autoimmune diseases, as well as neurological and mental disorders, has gained significant interest. A literature review with a search depth of 10 years is presented. A literature search was conducted in the elibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases using the key term «alexithymia.» Current evidence suggests a much more heterogeneous understanding of alexithymia in clinical practice during this period: a significant shift has been observed from interpreting alexithymia as a normal variation to considering it a neuropsychiatric syndrome. The paper discusses a new tool for assessing alexithymia, the relationship of alexithymia with post-stroke complications, multiple sclerosis, Parkinson’s disease, epilepsy, tendency to self-harm, and addictive behavior, autism spectrum disorders, post-traumatic stress; analyzes promising areas for further study of alexithymia, aimed at increasing the objectification of its level detection (neuroimaging, search for neurobiological specific features, registration of bioelectrical activity of the brain, and computer diagnostic methods), as well as the development of therapeutic strategies.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 16-24
Chronic traumatic encephalopathy
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts from contact sports, physical violence, and other causes. The urgency of the problem is due to the high incidence of pathology, not only in adults, but, most importantly, in the pediatric population. The paper presents a review of the literature in databases eLibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar with the key terms «head injury», «traumatic encephalopathy», «diagnosis», «treatment», «children and adolescents». The information obtained is analyzed, systematized and presented in three sections: general information about CTE; sports-related concussion; clinical and morphological picture of CTE; diagnostic criteria for traumatic encephalopathy syndrome; treatment of CTE. Neurofibrillary glomeruli (phospho-tau) formation, impaired amyloid beta elimination, impaired blood-brain barrier function, and low-intensity inflammation play an important role in the pathogenesis of CTE. The agreed diagnostic criteria for traumatic encephalopathy syndrome and the step-by-step diagnosis of this syndrome proposed in 2021 by the National Institute of Neurological Disorders and Stroke of the USA are outlined. Treatment includes symptomatic therapy for anxiety and depression, cognitive impairment, behavioral disorders, neuroprotectors, and non-drug intervention methods. Citicoline (Neipilept) and choline alfoscerate (Cereton) are considered as potential neuroprotectors.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 16-24
Chronic traumatic encephalopathy
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts from contact sports, physical violence, and other causes. The urgency of the problem is due to the high incidence of pathology, not only in adults, but, most importantly, in the pediatric population. The paper presents a review of the literature in databases eLibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar with the key terms «head injury», «traumatic encephalopathy», «diagnosis», «treatment», «children and adolescents». The information obtained is analyzed, systematized and presented in three sections: general information about CTE; sports-related concussion; clinical and morphological picture of CTE; diagnostic criteria for traumatic encephalopathy syndrome; treatment of CTE. Neurofibrillary glomeruli (phospho-tau) formation, impaired amyloid beta elimination, impaired blood-brain barrier function, and low-intensity inflammation play an important role in the pathogenesis of CTE. The agreed diagnostic criteria for traumatic encephalopathy syndrome and the step-by-step diagnosis of this syndrome proposed in 2021 by the National Institute of Neurological Disorders and Stroke of the USA are outlined. Treatment includes symptomatic therapy for anxiety and depression, cognitive impairment, behavioral disorders, neuroprotectors, and non-drug intervention methods. Citicoline (Neipilept) and choline alfoscerate (Cereton) are considered as potential neuroprotectors.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 43-49
Cardiogenic dementia
Generally, when discussing vascular diseases of the brain, practitioners refer to diseases of the large (cervicocephalic) and small (perforating) arteries, requiring a differentiated approach to diagnosis, treatment, and prevention. The anatomical and functional unity of the cardiovascular system makes this approach quite arbitrary. Unfortunately, it often escapes attention that the most important component of the cardiovascular system (heart) and its diseases play an important, often dominant role in the development of cerebrovascular disorders, including cognitive impairment and dementia. This paper presents a literature review spanning a 50-year search depth. A literature search was conducted in the eLibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases using the key terms «myocardial infarction», «heart failure», «myocardial disease», «cognitive impairment», and «dementia». Current evidence suggests a much broader understanding of the pathogenesis of a condition that was dubbed «cardiogenic dementia» almost half a century ago. The mechanisms underlying the development of encephalopathy in myocardial diseases include chronic brain hypoperfusion, chronic low-intensity inflammation, oxidative stress, damage to the blood-brain barrier, and hyperactivation of the renin-angiotensin-aldosterone system and the sympathetic nervous system.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 43-49
Cardiogenic dementia
Generally, when discussing vascular diseases of the brain, practitioners refer to diseases of the large (cervicocephalic) and small (perforating) arteries, requiring a differentiated approach to diagnosis, treatment, and prevention. The anatomical and functional unity of the cardiovascular system makes this approach quite arbitrary. Unfortunately, it often escapes attention that the most important component of the cardiovascular system (heart) and its diseases play an important, often dominant role in the development of cerebrovascular disorders, including cognitive impairment and dementia. This paper presents a literature review spanning a 50-year search depth. A literature search was conducted in the eLibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases using the key terms «myocardial infarction», «heart failure», «myocardial disease», «cognitive impairment», and «dementia». Current evidence suggests a much broader understanding of the pathogenesis of a condition that was dubbed «cardiogenic dementia» almost half a century ago. The mechanisms underlying the development of encephalopathy in myocardial diseases include chronic brain hypoperfusion, chronic low-intensity inflammation, oxidative stress, damage to the blood-brain barrier, and hyperactivation of the renin-angiotensin-aldosterone system and the sympathetic nervous system.